Αποτελέσματα αναζήτησης - "профилактическая терапия"

1

Academic Journal

Overcoming obstacles to effective treatment of patients with migraine (Statement of the expert group on optimizing treatment of patients with migraine) ; Преодолевая барьеры на пути эффективного ведения пациентов с мигренью (заявление экспертной группы по оптимизации помощи пациентам с мигренью)

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 17, No 2 (2025); 4-14 ; Неврология, нейропсихиатрия, психосоматика; Vol 17, No 2 (2025); 4-14 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2025-2

Θεματικοί όροι: профилактическая терапия мигрени, migraine, relief of migraine attacks, preventive therapy of migraine, мигрень, купирование приступов мигрени

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2476/1785; United Nations (2015). Transforming our world: the 2030 Agenda for Sustainable Development. United Nations, New York. A/RES/70/1. Available at: https://sdgs.un.org/sites/default/files/publications/21252030 Agenda for Sustainable Development web.pdf (accessed 01.06.2023).; Martelletti P, Leonardi M, Ashina M, et al. Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain. 2023 Oct 27;24(1):140. doi:10.1186/s10194-023-01666-2; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. doi:10.1016/S0140-6736(20)30925-9. Erratum in: Lancet. 2020 Nov 14;396(10262):1562. doi:10.1016/S0140-6736(20)32226-1; Dong L, Dong W, Jin Y, et al. The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region. Pain Ther. 2025 Feb;14(1):297-315. doi:10.1007/s40122-024-00690-7. Epub 2024 Dec 11.; Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022 Apr 12;23(1):34. doi:10.1186/s10194-022-01402-2; Blumenfeld AM. Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment. J Prim Care Community Health. 2020 Jan-Dec;11:2150132720959935. doi:10.1177/2150132720959935; Глембоцкая ГТ, Козуб ОВ. Фармако-экономическая оценка «бремени» мигрени в РФ. Клиническая фармакология и терапия. 2013;22(2):83-6.; Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021 Apr 21;22(1):29. doi:10.1186/s10194-021-01243-5; Begasse de Dhaem O, Sakai F. Migraine in the workplace. eNeurologicalSci. 2022 Jun 6;27:100408. doi:10.1016/j.ensci.2022.100408; Igarashi H, Sano H, Kondo H, et al. Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan. BMJ Open. 2024 Apr 29;14(4):e077686. doi:10.1136/bmjopen2023-077686; Brusa P, Allais G, Scarinzi C, et al. Selfmedication for migraine: A nationwide crosssectional study in Italy. PLoS One. 2019;14(1):e0211191. doi:10.1371/journal.pone.0211191; Ковальчук НА, Кирьянова ЕА, Табеева ГР. Приверженность терапии пациентов с мигренью (по данным интернетопроса). Неврология, нейропсихиатрия, психосоматика. 2021;13(4):81-7. doi:10.14412/2074-2711-2021-4-81-87; Gendolla A, Brown JD, Mercadante AR, et al. The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey. Cephalalgia. 2024 Dec;44(12):3331024241276415. doi:10.1177/03331024241276415; Gallup. Wellcome Global Monitor – First Wave Findings. 2019. Available at: https://wellcome.org/reports/wellcome-global-monitor/2018; Groth M, Katsarava Z, Ehrlich M. Results of the gErman migraine PatIent Survey on medical Care and prOPhylactic treatment Experience (EPISCOPE). Sci Rep. 2022 Mar 17;12(1):4589. doi:10.1038/s41598-022-08716-w; Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One. 2013;8(1):e54074. doi:10.1371/journal.pone.0054074. Epub 2013 Jan 16.; Shapiro RE, Nicholson RA, Seng EK, et al. Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life: Results of the OVERCOME (US) Study. Neurology. 2024 Feb 13;102(3):e208074. doi:10.1212/WNL.0000000000208074. Epub 2024 Jan 17.; Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi:10.1111/head.12499; Lipton RB, Munjal S, Buse DC, et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019 Sep;59(8):1310-23. doi:10.1111/head.13588. Epub 2019 Aug 13.; Bentivegna E, Galastri S, Onan D, Martelletti P. Unmet Needs in the Acute Treatment of Migraine. Adv Ther. 2024 Jan;41(1):1-13. doi:10.1007/s12325-023-02650-7. Epub 2023 Nov 9.; Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013 Sep;53(8):1300-11. doi:10.1111/head.12154. Epub 2013 Jul 23.; Smelt AF, Louter MA, Kies DA, et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS One. 2014 Jun 16;9(6):e98933. doi:10.1371/journal.pone.0098933; Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002 Jan;42 Suppl 1:3-9. doi:10.1046/j.1526-4610.2002.0420s1003.x; Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000 Jul;20(6):554-60. doi:10.1046/j.1468-2982.2000.00082.x; Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015 Feb 17;84(7):688-95. doi:10.1212/WNL.0000000000001256. Epub 2015 Jan 21.; Добрынина ЛА, Афанасьев МА, Белопасова АВ и др. Лечение эпизодической и хронической мигрени моноклональным антителом к кальцитонин-ген-родственному пептиду. Анналы клинической и экспериментальной неврологии. 2023;17(2):22-7. doi:10.54101/ACEN.2023.2.3; Meyers JL, Davis KL, Lenz RA, et al. Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi:10.1177/0333102419851855. Epub 2019 Jun 1.; Ueda K, Ye W, Lombard L, et al. Realworld treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019 Jun 7;20(1):68. doi:10.1186/s10194-019-1012-1; Martelletti P, Curto M. Unmet needs for migraine. Curr Med Res Opin. 2021 Nov;37(11):1957-9. doi:10.1080/03007995.2021.1976738. Epub 2021 Sep 16.; Matsumori Y, Ueda K, Komori M, et al. Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022 Mar;11(1):205-22. doi:10.1007/s40120-021-00305-9; Pascual J, Panni T, Dell'Agnello G, et al. Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. J Headache Pain. 2023 Jul 17;24(1):88. doi:10.1186/s10194-023-01623-z. Erratum in: J Headache Pain. 2023 Oct 20;24(1):142. doi:10.1186/s10194-023-01679-x; Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023 May 19;24(1):56. doi:10.1186/s10194-023-01594-1; Sacco S, Braschinsky M, Ducros A, et al. European Headache Federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020 Jun 16;21(1):76. doi:10.1186/s10194-020-01130-5; Мигрень. Взрослые. Клинические рекомендации МЗ РФ, 2024. Доступно по ссылке: https://base.garant.ru/410613100; Bentivegna E, Onan D, Martelletti P. Unmet Needs in Preventive Treatment of Migraine. Neurol Ther. 2023 Apr;12(2):337-42. doi:10.1007/s40120-023-00438-z. Epub 2023 Feb 4.; Азимова ЮЭ, Сергеев АВ, Осипова ВВ, Табеева ГР. Диагностика и лечение головных болей в России: результаты анкетного опроса врачей. Российский журнал боли. 2010;(4):12-7.; Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia. 2017 Apr;37(5):470-85. doi:10.1177/0333102416678382. Epub 2016 Nov 12.; Государственный реестр лекарственных средств. Доступно по ссылке: https://grls.rosminzdrav.ru/GRLS.aspx; Табеева ГР, Филатова ЕГ, Амелин АВ и др. Альтернативные и комплементарные методы лечения мигрени. Неврология, нейропсихиатрия, психосоматика. 2024;16(1):4-15. doi:10.14412/2074-2711-2024-1-4-15; Головачева ВА, Головачева АА. Когнитивно-поведенческая терапия в лечении пациентов с хронической мигренью и эмоциональными нарушениями: проспективное рандомизированное исследование с двухлетним периодом наблюдения. Consilium Medicum. 2024;26(11):745-51. doi:10.26442/20751753.2024.11.203055; Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18. doi:10.1016/S0140-6736(20)32342-4. Epub 2021 Mar 25.; Lenz B, Katsarava Z, Gil-Gouveia R, et al; European Headache Federation and Lifting The Burden: the Global Campaign against Headache. Headache service quality evaluation: implementation of quality indicators in primary care in Europe. J Headache Pain. 2021 Apr 28;22(1):33. doi:10.1186/s10194-021-01236-4; Kim BK, Chu MK, Yu SJ, et al. Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021 May 24;22(1):45. doi:10.1186/s10194-021-01250-6. Erratum in: J Headache Pain. 2021 Jun 11;22(1):56. doi:10.1186/s10194-021-01270-2; Edmeads J. Communication issues in migraine diagnosis. Can J Neurol Sci. 2002 Jun;29 Suppl 2:S8-10. doi:10.1017/s0317167100001876; Haghdoost F, Togha M. Migraine management: Non-pharmacological points for patients and health care professionals. Open Med (Wars). 2022 Nov 23;17(1):1869-82. doi:10.1515/med2022-0598; Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi:10.1038/s41582-021-00509-5. Epub 2021 Jun 18.; Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi:10.1177/0333102417738202; Cousins G, Hijazze S, Van de Laar FA, Fahey T. Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis. Headache. 2011 Jul-Aug;51(7):1140-8. doi:10.1111/j.1526-4610.2011.01916.x. Epub 2011 Jun 7.; Schwedt TJ, Lipton RB, Goadsby PJ, et al. Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening Period. Neurol Clin Pract. 2025 Feb;15(1):e200359. doi:10.1212/CPJ.0000000000200359. Epub 2024 Oct 8.; Fraser CL, Hepschke JL, Jenkins B, Prasad S. Migraine Aura: Pathophysiology, Mimics, and Treatment Options. Semin Neurol. 2019 Dec;39(6):739-48. doi:10.1055/s-0039-1700525. Epub 2019 Dec 17.; Pavlovic JM, Buse DC, Sollars CM, et al. Trigger factors and premonitory features of migraine attacks: summary of studies. Headache. 2014 Nov-Dec;54(10):1670-9. doi:10.1111/head.12468; American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan;59(1):1-18. doi:10.1111/head.13456. Epub 2018 Dec 10. Erratum in: Headache. 2019 Apr;59(4):650-1. doi:10.1111/head.13506; Moreno-Ajona D, Villar-Martinez MD, Goadsby PJ. New Generation Gepants: Migraine Acute and Preventive Medications. J Clin Med. 2022 Mar 16;11(6):1656. doi:10.3390/jcm11061656; Mitsikostas DD, Waeber C, Sanchez-Del-Rio M, et al. The 5-HT1F receptor as the target of ditans in migraine – from bench to bedside. Nat Rev Neurol. 2023 Aug;19(8):489-505. doi:10.1038/s41582-023-00842-x. Epub 2023 Jul 12.; Martelletti P, Luciani M, Spuntarelli V, Bentivegna E. Deprescribing in migraine. Expert Opin Drug Saf. 2021 Jun;20(6):623-5. doi:10.1080/14740338.2021.1907342. Epub 2021 Mar 25.; Lipton RB, Stewart WF, Stone AM, et al; Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000 Nov 22-29;284(20):2599-605. doi:10.1001/jama.284.20.2599; Tzankova V, Becker WJ, Chan TLH. Pharmacologic prevention of migraine. CMAJ. 2023 Feb 6;195(5):E187-E192. doi:10.1503/cmaj.221607; Pellesi L, Garcia-Azorin D, Rubio-Beltran E, et al. Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain. 2024 Dec 5;25(1):214. doi:10.1186/s10194-024-01925-w; Ferreira VL, Mainka FF, Wiens A, Pontarolo R. Effectiveness of Calcitonin GeneRelated Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies. Clin Drug Investig. 2023 Sep;43(9):669-80. doi:10.1007/s40261-023-01301-7. Epub 2023 Sep 4.; Özge A, Baykan B, Bicakci S, et al. Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications. Front Neurol. 2024 Jun 13;15:1402569. doi:10.3389/fneur.2024.1402569; Giri S, Tronvik E, Linde M, et al. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia. 2023 Apr;43(4):3331024231156922. doi:10.1177/03331024231156922; Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023 Apr;43(4):3331024231159366. doi:10.1177/03331024231159366. Erratum in: Cephalalgia. 2024 Jun;44(6):3331024241255216. doi:10.1177/03331024241255216; Табеева ГР, Кацарава З. Современная концепция патофизиологии и новые мишени терапии мигрени. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):143-52. doi:10.14412/2074-2711-2020-4-143-152; Сергеев АВ, Гузий ЕА, Ковальчук НА и др. Роль генов дофаминергической системы в развитии хронической мигрени и лекарственно-индуцированной головной боли. Российский журнал боли. 2024;22(4):24-9. doi:10.17116/pain20242204124; Belyaeva II, Subbotina AG, Eremenko II, et al. Pharmacogenetics in Primary Headache Disorders. Front Pharmacol. 2022 Feb 10;12:820214. doi:10.3389/fphar.2021.820214; Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013 Sep;53(8):1278-99. doi:10.1111/head.12150. Epub 2013 Jun 28.; Irimia P, Garcia-Azorin D, Nunez M, et al. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain. 2022 Jul 7;23(1):78. doi:10.1186/s10194-022-01448-2; Schwedt TJ, Buse DC, Argoff CE, et al. Medication Overuse and Headache Burden: Results From the CaMEO Study. Neurol Clin Pract. 2021 Jun;11(3):216-26. doi:10.1212/CPJ.0000000000001037; Ha H, Gonzalez A. Migraine Headache Prophylaxis. Am Fam Physician. 2019 Jan 1;99(1):17-24.; Pavelic AR, Wöber C, Riederer F, Zebenholzer K. Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of RealWorld Data. Cells. 2022 Dec 29;12(1):143. doi:10.3390/cells12010143; Табеева ГР, Косивцова ОВ, Ковальчук НА, Орлюк ТА. Рефрактерная мигрень. Неврология, нейропсихиатрия, психосоматика. 2024;16(2):76-86. doi:10.14412/2074-2711-2024-2-76-86; Ornello R, Andreou AP, De Matteis E, et al. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. 2024 Jan;99:104943. doi:10.1016/j.ebiom.2023.104943. Epub 2023 Dec 23.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2476
https://doi.org/10.14412/2074-2711-2025-2-4-14

View record from BASE

2

Academic Journal

Разработка новой рецептуры фиточая

Θεματικοί όροι: фиточай, лекарственные растения, компонентный состав, иммуностимуллирующая активность, профилактическая терапия, органолептические свойства

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://elib.belstu.by/handle/123456789/57455

3

Academic Journal

The First Experience of Using Botulinum Therapy for Chronic Migraine in Belarus

Πηγή: Неврология и нейрохирургия. Восточная Европа. :452-460

Θεματικοί όροι: индекс HIT-6, индекс HALT, HALT index, ботулинический токсин типа А, визуальная аналоговая шкала, профилактическая терапия, HIT-6 index, 3. Good health, botulinum toxin type A, visual analogue scale, 03 medical and health sciences, 0302 clinical medicine, preventive therapy, chronic migraine, хроническая мигрень

4

Academic Journal

Сравнительная эффективность и переносимость двухлетней противорецидивной терапии карбамазепином, карбонатом лития, флуоксетином и пароксетином у пациентов с рекуррентным депрессивным расстройством

Θεματικοί όροι: рекуррентное депрессивное расстройство, secondary preventive therapy, lithium carbonate, fluoxetine, пароксетин, флуоксетин, карбонат лития, нормотимики, вторичная профилактическая терапия, 3. Good health, карбамазепин, mood stabilizers, recurrent depressive disorder, carbamazepine, new generation antidepressants, антидепрессанты нового поколения, paroxetine

5

Academic Journal

Hierarchy of pathogenetic mechanisms of chronic cerebrovascular insufficiency and therapeutic strategies for neuroprotection ; Иерархия патогенетических механизмов хронической недостаточности мозгового кровообращения и терапевтических стратегий нейропротекции

Συγγραφείς: M. V. Putilina, М. В. Путилина

Πηγή: Meditsinskiy sovet = Medical Council; № 3 (2023); 17-23 ; Медицинский Совет; № 3 (2023); 17-23 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: полипептид из головного мозга эмбрионов свиней, preventive therapy, symptomatic therapy, neuropeptides, porcine brain polypeptide, профилактическая терапия, симптоматическая терапия, нейропептиды

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7407/6624; Zhou D., Meng R., Li S.J., Ya J.Y., Ding J.Y., Shang S.L. et al. Advances in chronic cerebral circulation insufficiency. CNS Neurosci Ther. 2018;24(1):5–17. https://doi.org/10.1111/cns.12780.; Feigin V.L., Stark B.A., Johnson C.O., Roth G.A., Bisignano C., Anderson J.A. et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the GlobalBurden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. https://doi.org/10.1016/S1474-4422(21)00252-0.; Tong X., Yang Q., Ritchey M.D., George M.G., Jackson S.L., Gillespie C., Merritt R.K. The Burden of Cerebrovascular Disease in the United States. Prev Chronic Dis. 2019;16:E52. https://doi.org/10.5888/pcd16.180411.; Parfenov V.A. Diagnosis and treatment of chronic cerebrovascular disease, use of pentoxifylline. Neurology, neuropsychiatry, psychosomatics. 2016;8(3):4–9. https://doi.org/10.14412/2074-2711-2016-3-4-9.; Путилина М.В. Нейропротекторная терапия хронической ишемии головного мозга. Врач. 2008;(8):27–32. Режим доступа: https://www.elibrary.ru/download/elibrary_12952445_20568520.pdf.; Путилина М.В. Эндотелий – мишень для новых терапевтических стратегий при сосудистых заболеваниях головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(10):122–130. https://doi.org/10.17116/jnevro2017117101122-130.; Golanov E., Regnier-G olanov A., Britz G. Multifactorial neuroprotection: Does the brain have an answer? Conditioning Medicine. 2019;2(2):75–89. Available at: https://www.researchgate.net/publication/332971133_Conditioning_Medicine_Multifactorial_neuroprotection_Does_the_brain_have_an_answer.; Hannan M.A., Dash R., Sohag A.A.M., Haque M.N., Moon I.S. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020;(13):116. https://doi.org/10.3389/fnmol.2020.00116.; Favreault M.M., Johnson R.W. The Risk and Costs of Severe Cognitive Impairment at Older Ages: Literature Review and Projection Analyses. Urban Institute. 2021. Available at: https://aspe.hhs.gov/reports/risk-costs-severecognitive-impairment-older-ages-literature-review-projection-analyses-0.; Dutta R. Central nervous system diseases associated with blood brain barrier breakdown - A Comprehensive update of existing literature. J Neurosci Neurol Disord. 2020;4:053–062. https://doi.org/10.29328/journal.jnnd.1001035.; Sweeney M.D., Zhao Z., Montagne A., Nelson A.R., Zlokovic B.V. Blood- Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 2019;99(1):21–78. https://doi.org/10.1152/physrev.00050.2017.; Crockett A.M., Ryan S.K., Vásquez A.H., Canning C., Kanyuch N., Kebir H. et al. Disruption of the blood- brain barrier in 22q11.2 deletion syndrome. Brain. 2021;144(5):1351–1360. https://doi.org/10.1093/brain/awab055.; Giacobbo L.B., Doorduin J., Klein H.C., Dierckx R.A.J.O., Bromberg E., de Vries E.F.J. Brain- Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2019;56(5):3295–3312. https://doi.org/10.1007/s12035-018-1283-6.; Profaci C.P., Munji R.N., Pulido R.S., Daneman R. The blood-b rain barrier in health and disease: Important unanswered questions. J Exp Med. 2020;217(4):e20190062. https://doi.org/10.1084/jem.20190062.; Путилина М.В. Нейропластичность как основа ранней реабилитации пациентов после инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(12–2):64–69. Режим доступа: https://www.elibrary.ru/pywskz.; Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина; 2001. 328 с. Режим доступа: https://med-books.by/nevrologiya/2350-ishemiya-golovnogo-mozga-gusev-ei-skvorcova-vi-2001-god-328-s.html.; Путилина М.В. Современные представления о болезни мелких сосудов головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(11):65–73. https://doi.org/10.17116/jnevro201911911165.; Громова О.А., Торшин И.Ю., Путилина М.В., Семенов В.А., Рудаков К.В. Выбор нейропротективной терапии у пациентов с хронической ишемией головного мозга с учетом синергизма лекарственных взаимодействий. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(8):42–50. https://doi.org/10.17116/jnevro202012008142.; Хавинсон В.Х. Лекарственные пептидные препараты: прошлое, настоящее, будущее. Клиническая медицина. 2020;98(3):165–177. https://doi.org/10.30629/0023-2149-2020-98-3-165-177.; Zhou X., Smith Q.R., Liu X. Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood- brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(4):e1695. https://doi.org/10.1002/wnan.1695.; Lau J.L., Dunn M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707. https://doi.org/10.1016/j.bmc.2017.06.052.; Soudy R., Kimura R., Patel A. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Sci Rep. 2019;9(1):10942. https://doi.org/10.1038/s41598-019-47255-9.; Камчатнов П.Р., Абусуева Б.А., Ханмурзаева С.Б., Митяева Е.В., Чипова Д.Т., Малашенков Н.Д. Результаты оценки эффективности применения препарата Целлекс у пациентов с болезнью мелких сосудов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(1):67–74. https://doi.org/10.17116/jnevro202312301167.; Абусуева Б.А., Евзельман М.А, Камчатнов П.Р., Умарова Х.Я. Применение препарата Целлекс у пациентов с хронической ишемией головного мозга и умеренными когнитивными нарушениями. Нервные болезни. 2016;2:29–34. Режим доступа: https://cyberleninka.ru/article/n/primenenie-preparata-tselleks-u-patsientov-s-hronicheskoy-ishemieygolovnogo- mozga-i-umerennymi- kognitivnymi-narusheniyami.; Коваленко А.В., Сафронова М.Н. Влияние целлекса на восстановление когнитивных и речевых нарушений в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(1):40–44.; Tanaka M., Vécsei L. Editorial of Special Issue Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection. Int J Mol Sci. 2022;23(13):6991. https://doi.org/10.3390/ijms23136991.; Путилина М.В. Коморбидный пациент в реальной клинической практике. Consilium Medicum. 2017;19(2):71–79. Режим доступа: https://journals.eco-vector.com/2075-1753/article/view/94738?ysclid=lecr0crssr470786300.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/7407
https://doi.org/10.21518/ms2023-042

View record from BASE

6

Academic Journal

Medication adherence in migraine patients (data of an online survey) ; Приверженность терапии пациентов с мигренью (по данным интернет-опроса)

Συγγραφείς: N. A. Kovalchuk, E. A. Kiryanova, G. R. Tabeeva, Н. А. Ковальчук, Е. А. Кирьянова, Г. Р. Табеева

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 4 (2021); 81-87 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 4 (2021); 81-87 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-4

Θεματικοί όροι: приверженность терапии, migraine preventive therapy, medication adherence, профилактическая терапия мигрени

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1634/1285; GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-80. doi:10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.; Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: Effects of sex, income, and headache features. Headache. 2013 Jan;53(1):81-92. doi:10.1111/j.1526-4610.2012.02265.x. Epub 2012 Oct 18.; Peh KQE, Kwan YH, Goh H, et al. An Adaptable Framework for Factors Contributing to Medication Adherence: Results from a Systematic Review of 102 Conceptual Frameworks. J Gen Intern Med. 2021 Mar 3. doi:10.1007/s11606-021-06648-1. Epub ahead of print.; Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013 Apr;53(4):644-55. doi:10.1111/head.12055. Epub 2013 Mar 4.; Dodick DW, Loder EW, Manack Adams A, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016 May;56(5):821-34. doi:10.1111/head.12774. Epub 2016 May 3.; Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to Acute Migraine Medication: What Does It Mean, Why Does It Matter? Headache. 2010 Jan;50(1):117-29. doi:10.1111/j.1526-4610.2009.01535.x. Epub 2009 Oct 8.; Lipton RB, Dodick D, Sadovsky R, et al; ID Migraine validation study. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003 Aug 12;61(3):375-82. doi:10.1212/01.wnl.0000078940.53438.83; Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care. 1986 Jan;24(1):67-74. doi:10.1097/00005650-198601000-00007; Табеева ГР. Лечение приступа мигрени: пути оптимизации терапевтических подходов. Нервные болезни. 2015;(3):2-8.; Филатова ЕГ, Осипова ВВ, Табеева ГР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. doi:10.14412/2074-27112020-4-4-14; World Health Organisation. Adherence to long-term therapies, evidence for action. Geneva; 2003 Available from: http://www.who.int2; Fernandez-Lazaro CI, Garcia-Gonzalez JM, Adams DP, et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Fam Pract. 2019 Sep 14;20(1):132. doi:10.1186/s12875-019-1019-3; Россияне борются с недомоганиями: безрецептурный препарат или народная медицина вместо визита к врачу. Исследование Nielsen. Доступно по ссылке: www.acnielsen.ru; Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006 Jul 1;333(7557):15. doi:10.1136/bmj.38875.675486.55. Epub 2006 Jun 21.; Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013 Sep;53(8):1300-11. doi:10.1111/head.12154. Epub 2013 Jul 23.; Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache. Nov-Dec 2012;52(10):1456-70. doi:10.1111/j.1526-4610.2012.02223.x. Epub 2012 Jul 25.; Ayzenberg I, Katsarava Z, Sborowski A, et al. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014 May;21(5):758-65. doi:10.1111/ene.12380. Epub 2014 Feb 13.; Ayzenberg I, Katsarava Z, Mathalikov R, et al. The burden of headache in Russia: validation of the diagnostic questionnaire in a population-based sample. Eur J Neurol. 2011 Mar;18(3):454-9. doi:10.1111/j.1468-1331.2010.03177.x. Epub 2010 Aug 16.; Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi:10.1177/0333102412438977. Epub 2012 Mar 6.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1634
https://doi.org/10.14412/2074-2711-2021-4-81-87

View record from BASE

7

Academic Journal

Clinical-anamnestic indicators of the efficiency of alternative regimens of preventive therapy of bronchial asthma in children ; Клинико-анамнестические показатели эффективности альтернативных режимов профилактической терапии бронхиальной астмы у детей ; Клінічно-анамнестичні показники ефективності альтернативних режимів профілактичної терапії бронхіальної астми в дітей

Συγγραφείς: Сажин, С.

Πηγή: Bukovinian Medical Herald; Vol. 14 No. 3 (55) (2010); 76-78 ; Буковинский медицинский вестник; Том 14 № 3 (55) (2010); 76-78 ; Буковинський медичний вісник; Том 14 № 3 (55) (2010); 76-78 ; 2413-0737 ; 1684-7903

Θεματικοί όροι: бронхіальна астма, діти, профілактична терапія, бронхиальная астма, дети, профилактическая терапия, bronchial asthma, children, preventive treatment

Περιγραφή αρχείου: application/pdf

Relation: http://e-bmv.bsmu.edu.ua/article/view/245913/243412

Διαθεσιμότητα: http://e-bmv.bsmu.edu.ua/article/view/245913

View record from BASE

8

Academic Journal

Clinical-anamnestic indicators of the efficiency of alternative regimens of preventive therapy of bronchial asthma in children

Πηγή: Bukovinian Medical Herald; Vol. 14 No. 3 (55) (2010); 76-78
Буковинский медицинский вестник; Том 14 № 3 (55) (2010); 76-78
Буковинський медичний вісник; Том 14 № 3 (55) (2010); 76-78

Θεματικοί όροι: бронхиальная астма, дети, профилактическая терапия, бронхіальна астма, діти, профілактична терапія, bronchial asthma, children, preventive treatment, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://e-bmv.bsmu.edu.ua/article/view/245913

View record at OpenAIRE

9

Academic Journal

Диагностика и лечение мигрени: рекомендации российских экспертов ; Diagnosis and treatment of migraine: Russian experts' recommendations

Συγγραφείς: Filatova, E. G., Osipova, V. V., Tabeeva, G. R., Parfenov, V. A., Ekusheva, E. V., Azimova, Yu. E., Latysheva, N. V., Naprienko, M. V., Skorobogatykh, K. V., Sergeev, A. V., Golovacheva, V. A., Lebedeva, E. R., Artyomenko, A. R., Kurushina, O. V., Koreshkina, M. I., Amelin, A. V., Akhmadeeva, L. R., Rachin, A. P., Isagulyan, E. D., Danilov, Al. B., Gekht, A. B., Азимова, Ю. Э., Латышева, Н. В., Наприенко, М. В., Скоробогатых, К. В., Сергеев, А. В., Головачева, В. А., Лебедева, Е. Р., Артёменко, А. Р., Курушина, О. В., Корешкина, М. И., Амелин, А. В., Ахмадеева, Л. Р., Рачин, А. П., Исагулян, Э. Д., Данилов, Ал. Б., Гехт, А. Б.

Θεματικοί όροι: MIGRAINE, DIAGNOSIS, TREATMENT, CLINICAL GUIDELINES, PREVENTIVE THERAPY, SEIZURE RELIEF THERAPY, NON-DRUG METHODS, МИГРЕНЬ, ДИАГНОСТИКА, ЛЕЧЕНИЕ, КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ, ПРОФИЛАКТИЧЕСКАЯ ТЕРАПИЯ, ТЕРАПИЯ ДЛЯ КУПИРОВАНИЯ, НЕЛЕКАРСТВЕННЫЕ МЕТОДЫ

Περιγραφή αρχείου: application/pdf

Relation: Scopus; http://elib.usma.ru/handle/usma/7181

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7181

View record from BASE

10

Academic Journal

Drug-induced headache: an analysis of therapeutic strategies ; Лекарственно-индуцированная головная боль: анализ терапевтических стратегий

Συγγραφείς: P. A. Merbaum, G. R. Tabeeva, A. V. Sergeev, П. А. Мербаум, Г. Р. Табеева, А. В. Сергеев

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 4 (2020); 25-31 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 4 (2020); 25-31 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-4

Θεματικοί όροι: прогноз, educational talk, withdrawal therapy, prevention therapy for drug-induced headache, risk factors, druginduced refractory headache, prognosis, образовательная беседа, терапия отмены, профилактическая терапия лекарственно-индуцированной головной боли, факторы риска, рефрактерная лекарственно-индуцированная головная боль

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1407/1088; Bendtsena L, Eversb S, Lindec M, et al. EFNS guideline on the treatment of tension-type headache – Report of an EFNS task force. Eur J Neurol. 2010 Nov;17(11):1318-25. doi:10.1111/j.1468-1331.2010.03070.x; Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709-20. doi:10.2147/NDT.S33769; Ахмадеева ЛР, Азимова ЮЭ, Каракулова ЮВ и др. Клинические рекомендации по диагностике и лечению головной боли напряжения. РМЖ. 2016;(7):411-9.; Российское общество по изучению головной боли. Клинические рекомендации по ведению взрослых пациентов с мигренью. Российское общество по изучению головной боли (РОИГБ), Всероссийское общество неврологов (ВОН), 2016 г. Доступно по ссылке: https://medi.ru/klinicheskierekomendatsii/migren-u-vzroslykh_14074/; Da Silva AN, Lake AE. Clinical aspects of medication overuse headaches. Headache: J Head Face Pain. 2013;54(1):211-7. doi:10.1111/head.12223; Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: Epidemiology and impact on quality of life. Neurology. 2004;62(8):1338-42. doi:10.1212/01.WNL.0000120545.45443.93; Headache Classification Committee of the International Headache Society (2018) Headache classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3 rd edition. Cephalalgia. 2018;38:1-211. doi:10.1177/0333102417738202; Saper J, Lake A. Medication overuse headache: type I and type II. Cephalalgia. 2006;26(10):1262. doi:10.1111/j.14682982.2006.01198.x; Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011 Mar;18(3):396-401. doi:10.1111/j.14681331.2010.03157.x; Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006 Sep;26(9):1097-105. doi:10.1111/j.14682982.2006.01175.x; Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13:281-90. doi:10.1007/s10194-0120432-y; Bekkelund SI, Salvesen R. Patient satisfaction with a neurological specialist consultation for headache. Scand J Prim Health Care. 2002;20:157-60. doi:10.1080/028134302760234609; Hedenrud T, Babic N, Jonsson P. Medication overuse headache: self-perceived and actual knowledge among pharmacy staff. Headache. 2014 Jun;54(6):1019-25. doi:10.1111/head.12350; Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018 Jun;38(7):1316-25. doi:10.1177/0333102417736898; Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: The effect of a 2-month drug-free period. Neurology. 2006;66(12):1894-8. doi:10.1212/01.wnl.0000217914.30994.bd; Nielsen M, Carlsen LN, Munksgaard SB, et al. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2019 Jun;39(7):863-72. doi:10.1177/0333102419828994; Katsarava Z, Obermann M. Medicationoveruse headache. Curr Opin Neurol. 2013 Jun;26(3):276-81. doi:10.1097/WCO.0b013e328360d596; Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur J Neurol. 2011 Sep;18(9):1115-21. doi:10.1111/j.14681331.2011.03497.x; Kristoffersen ES, Lundqvist C. Medicationoveruse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014 Apr;5(2):87-99. doi:10.1177/2042098614522683; Bottiroli S, Allena M, Sances G, et al. COMOESTAS Consortium. Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A sixmonth follow-up of the COMOESTAS Project. Cephalalgia. 2018 Jan 1:333102418783317. doi:10.1177/0333102418783317; Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014;34(9):645-55. doi:10.1177/0333102414521508; Weatherall MW, Telzerow AJ, Cittadini E, et al. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology. 2010;75(12):1098-103. doi:10.1212/WNL.0b013e3181f39a11; Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995-7. doi:10.1212/WNL.36.7.995; Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache J Head Face Pain. 1987;27:130-3. doi:10.1111/j.1526-4610.1987.hed2703130.x; Probyn K, Bowers H, Caldwell F, et al. Prognostic factors for chronic headache. Neurology. 2017;89:291-301. doi:10.1212/WNL.0000000000004112; Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827-32. doi:10.1212/WNL.0b013e3182377dbb; Cevoli S, Giannini G, Favoni V, et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain. 2017;18(1):56. doi:10.1186/s10194-017-0763-9; Diener HC, Bussone G, van Oene JC, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23. doi:10.1111/j.1468-2982.2007.01326.x; Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo controlled trial. Headache. 2007;47:170-80. doi:10.1111/j.15264610.2006.00684.x; Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358-73. doi:10.1111/j.15264610.2011.01990.x; Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2015;36:371-86. doi:10.1177/0333102415593088; Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate, 2018. J Headache Pain. 2018;19(1):50. doi:10.1186/s10194-018-0875-x; Mark W. The diagnosis and treatment of chronic migraine. Weatherall Ther Adv Chronic Dis. 2015 May;6(3):115-23. doi:10.1177/2040622315579627; Ghadiri-Sani M, Silver N. Headache (chronic tension-type). BMJ Clin. Evid. 2016;5:1205.; Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol. 2012 Jun;25(3):290-5. doi:10.1097/WCO.0b013e328352c431; Silberstein SD, Blumenfeld AM, Cady RK, et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48-56. doi:10.1016/j.jns.2013.05.003; Tepper SJ, Dinner H-C, Ashina M, et al. Erenumab in patients with chronic migraine with medication overuse. Neurology. 2019 May 14;92(20):2309-20. doi:10.1212/WNL.0000000000007497; Hagen K, Jensen R, Boe MG, Stovner LJ. Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. 2010 Oct;11(5):373-7. doi:10.1007/s10194-010-0221-4; Zidverc-Trajkovic JJ, Pekmezovic T, Jovanovic Z, et al. Long-term predictors of remission in patients treated for medicationoveruse headache at a specialized headache center: A prospective cohort study. Cephalalgia. 2016;0(0):1-9.; Boe MG, Thortveit E, Vatne A, Mygland A. Chronic headache with medication overuse: Long-term prognosis after withdrawal therapy. Cephalalgia. 2016;37(13):1215-21. doi:10.1177/0333102416672493; Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12-5. doi:10.1111/j.14682982.2004.00789.x; Schnider P, Aull S, Baumgartner C, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up. Cephalalgia. 1996;16:481-5. doi:10.1046/j.1468-2982.1996.1607481.x; Suhr B, Evers S, Bauer B, et al. Druginduced headache: long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia. 1999;19:44-9. doi:10.1111/j.14682982.1999.1901044.x; Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: longterm follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol. 2001;45:229-35. doi:10.1159/000052134; Pini L-A, Cicero A, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia. 2001;21:878-83. doi:10.1046/j.14682982.2001.00288.x; Sances G, Ghiotto N, Galli F, et al. Risk factors in medication-overuse headache: a 1-year follow-up study (care II protocol). Cephalalgia. 2010;30:329-36. doi:10.1111/j.1468-2982.2009.01934.x; Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007;27:1219-25. doi:10.1111/j.1468-2982.2007.01432.x; Munksgaard S, Bendtsen L, Jensen R. Treatment resistant medication overuse headache can be cured. Headache. 2012;52:1120-9. doi:10.1111/j.1526-4610.2012.02191.x; Rossi P, Jensen J, Nappi G, Allena M. The COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain. 2009;10:407-17. doi:10.1007/s10194-009-0159-6; Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26(10):1192-8. doi:10.1111/j.1468-2982.2006.01190.x; Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006 Sep-Oct;29(5):269-75. doi:10.1097/01.WNF.000022888.49044.99; De Goffau MJ, Klaver ARE, Willemsen MG, et al. The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain. 2017;18(6):615-27. doi:10.1016/j.jpain.2016.12.005

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1407
https://doi.org/10.14412/2074-2711-2020-4-25-31

View record from BASE

11

Academic Journal

Diagnosis and treatment of migraine: Russian experts' recommendations ; Диагностика и лечение мигрени: рекомендации российских экспертов

Συγγραφείς: E. G. Filatova, V. V. Osipova, G. R. Tabeeva, V. A. Parfenov, E. V. Ekusheva, Yu. E. Azimova, N. V. Latysheva, M. V. Naprienko, K. V. Skorobogatykh, A. V. Sergeev, V. A. Golovacheva, E. R. Lebedeva, A. R. Artyomenko, O. V. Kurushina, M. I. Koreshkina, A. V. Amelin, L. R. Akhmadeeva, A. R. Rachin, E. D. Isagulyan, Al. B. Danilov, A. B. Gekht, Е. Г. Филатова, В. В. Осипова, Г. Р. Табеева, В. А. Парфенов, Е. В. Екушева, Ю. Э. Азимова, Н. В. Латышева, М. В. Наприенко, К. В. Скоробогатых, А. В. Сергеев, В. А. Головачева, Е. Р. Лебедева, А. Р. Артёменко, О. В. Курушина, М. И. Корешкина, А. В. Амелин, Л. Р. Ахмадеева, А. П. Рачин, Э. Д. Исагулян, Ал. Б. Данилов, А. Б. Гехт

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 4 (2020); 4-14 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 4 (2020); 4-14 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-4

Θεματικοί όροι: нелекарственные методы, diagnosis, treatment, clinical guidelines, preventive therapy, seizure relief therapy, non-drug methods, диагностика, лечение, клинические рекомендации, профилактическая терапия, терапия для купирования

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1404/1085; Амелин АВ, Игнатов ЮД, Скоромец АА, Соколов АЮ. Мигрень (патогенез, клиника, лечение). Москва: МЕДпресс; 2011. 265 с.; Осипова ВВ, Табеева ГР. Первичные головные боли: диагностика, клиника, терапия: Практическое руководство. Москва: Медицинское информационное агентство; 2014. 336 с.; Табеева ГР, Яхно НН. Мигрень. Москва: ГЭОТАР-Медиа; 2011. 622 с.; Сергеев АВ, Табеева ГР, Азимова ЮЭ. Центральная нейрональная гипервозбудимость – предиспозиция к мигрени. Российский журнал боли. 2010;2(27):3-11.; Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol. 1991;44:1147-57. doi:10.1016/08954356(91)90147-2; Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32(5):373-81. doi:10.1177/0333102412438977; Лебедева ЕР, Кобзева НР, Гилев ДВ, Олесен Ес. Анализ качества диагностики и лечения первичных головных болей в различных социальных группах Уральского региона. Неврология, нейропсихиатрия, психосоматика. 2015;7(1):19-26. doi:10.14412/2074-2711-2015-1-19-26; GBD 2015 Neurological Disorders Collaborator Group Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017 Nov;16(11):877-89.; Яхно НН, Парфенов ВА, Алексеев ВВ. Головная боль (справочное руководство для врачей). Москва: Р-врач; 2000. 150 с.; Парфенов ВА, Головачева ВА. Хроническая боль и ее лечение в неврологии. Москва: ГЭОТАР-Медиа; 2018.; Головачева ВА, Парфенов ВА, Табеева ГР и др. Оптимизация ведения пациентов с хронической ежедневной головной болью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(2):4-9. doi:10.17116/jnevro2017117214-9; Головачева ВА, Парфенов ВА. Когнитивно-поведенческая терапия в лечении хронической ежедневной головной боли. Анналы клинической и экспериментальной неврологии. 2019;13(3):63-70. doi:10.25692/ACEN.2019.3; Осипова ВВ, Азимова ЮЭ, Табеева ГР и др. Диагностика головных болей в России и странах постсоветского пространства: состояние проблемы и пути ее решения. Анналы клинической и экспериментальной неврологии. 2012;6(2):16-21.; Тарасова СВ, Амелин АВ, Скоромец АА. Распространенность и выявляемость первичных и симптоматических форм хронической ежедневной головной боли. Казанский медицинский журнал. 2008;89(4):427-31.; Kowacs PA, Twardowschy CA, Piovesan EJ, et al. General practice physician knowledge about headache: evaluation of the municipal continual medical education program. Arq Neuro-Psiquiatr. 2009;67:3. doi:10.1590/s0004-282x2009000400004; Cevoli S, D'Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of survey migraine in Italy: a survey of patients attending for the first time 10 headache centers. Cephalalgia. 2009;29:1285-93. doi:10.1111/j.1468-2982.2009.01874.x; The International Classification of Headache Disorders, 3 rd edition (ICHD-3). Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202; Осипова ВВ. Мигрень и головная боль напряжения. В кн.: Гусев ЕИ, Коновалов АН, редакторы. Клинические рекомендации. Неврология и нейрохирургия. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа; 2015. 424. с.; Lebedeva ER, Gurary NM, Gilev DV, Olesen J. Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia. 2018;38(3):561-7. doi:10.1177/0333102417702121; Lebedeva ER, Gurary NM, Gilev DV, et al. Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. Cephalalgia. 2018;38(8):1463-70. doi:10.1177/0333102417736901; Екушева ЕВ, Карпова МИ, Осипова ВВ. Гормональные контрацептивы и риск ишемического инсульта у женщин с мигренью: новый международный консенсус. Неврология, нейропсихиатрия и психосоматика. 2019;11(3):11-5. doi:10.14412/2074-2711-2019-3-11-15; Lipton RB, Serrano D, Buse DC, et al. Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia. 2016;36(3):203-15. doi:10.1177/0333102415583982; Артеменко АР, Куренков АЛ, Беломестова КВ. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;(11):91-6.; Zeeberg P, Olesen J, Jensen R. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria. Cephalalgia. 2009;29(2):214-20. doi:10.1111/j.1468-2982.2008.01710.x; Осипова ВВ, Филатова ЕГ, Артеменко АР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журнал неврологии и психиатрии им. Корсакова 2017;(2):28-42.; Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache. 3 rd ed. British Association for the Study of Headache; 2007.; Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society. 2 nd ed, 2012. J Headache Pain. 2012;13:S1-S29. doi:10.1007/s10194-011-0402-9; Mitsikostas D, Ashina M, Craven A, et al. EHF committee. European Headache Federation Consensus on Technical Investigation for Primary Headache Disorders. J Headache Pain. 2015;17:5. doi:10.1186/s10194-016-0596-y; Academy of Neurology. The utility of neuroimaging in the evaluation of headache in patients with normal neurological examinations. Neurology. 1994;44:1353-4. doi:10.1212/WNL.44.7.1353; Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol. 2008;21(3):331-7. doi:10.1097/WCO.0b013e3282fee843; Orr SL, Aube M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35:271. doi:10.1177/0333102414535997; Kirthi V, Derry S, Moore R. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008041. doi:10.1002/14651858.CD008041.pub3; Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254(6):705-12. doi:10.1007/s00415-007-0547-2; Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41(11):1782-91. doi:10.1345/aph.1K121; Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008039. doi:10.1002/14651858.CD008039.pub3; Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50(5):808-18. doi:10.1111/j.1526-4610.2010.01635.x; Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;10:CD009455. doi:10.1002/14651858.CD009455.pub2; Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008783. doi:10.1002/14651858.CD008039.pub3; Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008040. doi:10.1002/14651858.CD008040.pub3; Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, doubleblind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537-47. doi:10.1111/j.1468-2982.2005.01064.x; Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369-73. doi:10.1136/bmj.38281.595718.7C; Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med. 1996;156:1725-8. doi:10.1001/archinte.1996.00440140163017; Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi:10.1111/head.12601; Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-58. doi:10.1046/j.14682982.2002.00404.x; Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication. A review. Cephalalgia. 2004;24:321-32. doi:10.1111/j.1468-2982.2003.00690.x; Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007;47:1152-68. doi:10.1111/j.1526-4610.2007.00849.x; Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001:CD003224. doi:10.1002/14651858.CD003224.pub2; Филатова ЕГ, Амелин АВ, Табеева ГР и др. Ready – первое российское мультицентровое исследование эффективности препарата релпакс (элетриптан) при лечении мигрени. Лечение нервных болезней. 2006;(2):19-22.; Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-8. doi:10.1016/S07364679(02)00502-4; Gungor F, Akyol KC, Kesapli M, et al. Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial. Cephalalgia. 2016;36:179-84. doi:10.1177/0333102415584604; Duarte C, Dunaway F, Turner L, et al. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: A randomized, prospective, double-blind trial. Ann Emerg Med. 1992;21:1116-21. doi:10.1016/S0196-0644(05)80654-7; Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura: A randomized, doubleblind, placebo-controlled study. Cephalalgia. 2002;22:345-53. doi:10.1046/j.14682982.2002.00364.x; Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38:621-7. doi:10.1067/mem.2001.119424; Cete Y, Dora B, Ertan C, et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005;25:199-204. doi:10.1111/j.1468-2982.2004.00840.x; Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005;45:42-6. doi:10.1111/j.15264610.2005.05009.x; Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: A prospective, randomized, doubleblind trial. Ann Emerg Med. 2003;41:847-53. doi:10.1067/mem.2003.195; Woldeamanuel YW, Rapoport AM, Cowan RP. The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia. 2015;35(11):996-1024. doi:10.1177/0333102414566200; Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69:2038-44. doi:10.1212/01.WNL.0000281105.78936.1d; Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359-61. doi:10.1136/bmj.39566.806725.BE; Neill A, Brannigan D. Towards evidencebased emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 2: Dexamethasone for reduction of migraine recurrence. Emerg Med J. 2013;30:165-6. doi:10.1136/emermed-2012-202190.3; Dekker F, Neven AK, Andriesse B, et al. Prophylactic treatment of migraine by GPs: a qualitative study. Br J Gen Pract. 2012;62(597):268-74. doi:10.3399/bjgp12X636100; Jackson JL, Cogbill E, Santana-Davila R, et al. Comparative effectiveness meta-analysis of drugs for the pophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733. doi:10.1371/journal.pone.0130733; He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):26. doi:10.1186/s10194-017-0720-7; Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache. 1991;31(5):333-40. doi:10.1111/j.15264610.1991.hed3105333.x; Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A doubleblind study. Cephalalgia. 1984;4:91-6. doi:10.1046/j.1468-2982.1984.0402091.x; Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2016;5:CD003226. doi:10.1002/14651858.CD003226.pub3; Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611. doi:10.1002/14651858.CD010611; Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract. 2005;59:961-8. doi:10.1111/j.1368-5031.2005.00612.x; Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170-80. doi:10.1111/j.15264610.2006.00684.x; Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616. doi:10.1002/14651858.CD011616.pub2; Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-37. doi:10.1177/0333102418759786; Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine a randomized clinical trial. JAMA. 2018;319(19):1999-2008. doi:10.1001/jama.2018.4853; Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab forpreventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-34. doi:10.1016/S1474-4422(17)30083-2; Bigal M, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081-90. doi:10.1016/S1474-4422(15)00249-5; Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:c5222. doi:10.1136/bmj.c5222; Xu XM, Yang C, Liu Y, et al. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur J Neurol. 2017;24(8):1022-31. doi:10.1111/ene.13320; Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44-8. doi:10.1016/j.clineuro.2004.03.004; Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:144-52. doi:10.1111/j.15264610.2005.05029.x; Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-9. doi:10.1001/jama.289.1.65; Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double crossover study. Cephalalgia. 2014;34(7):523-32. doi:10.1177/0333102413515348; Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia. 2016;36:371-86. doi:10.1177/0333102415593088; De Goffau MJ, Klaver ARE, Willemsen MG, et al. The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain. 2017;18(6):615-27. doi:10.1016/j.jpain.2016.12.005; Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: A multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12:427-33. doi:10.1007/s10194-011-0339-z; Silberstein SD, Blumenfeld AM, Cady R, et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48-56. doi:10.1016/j.jns.2013.05.003; Kristoffersen ES, Straand J, Vetvik KG, et al. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry. 2015;86(5):505-10. doi:10.1136/jnnp-2014-308548; Hagen K, Albretsen C, Vilming ST, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29:221-32. doi:10.1111/j.1468-2982.2008.01711.x; Bottiroli S, Allena M, Sances G, et al; COMOESTAS Consortium. Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A sixmonth follow-up of the COMOESTAS Project. Cephalalgia. 2018;1:333102418783317. doi:10.1177/0333102418783317; Luedtke K, Allers A, Schulte LH, May A. Efficacy of interventions used by physiotherapists for patients with headache and migraine. Systematic review and meta-analysis. Cephalalgia. 2016;36(5):474-92. doi:10.1177/0333102415597889; Millstine D, Chen CY, Bauer B. Complementary and integrative medicine in the management of headache. BMJ. 2017;16;357:j1805. doi:10.1136/bmj.j1805; Giannitrapani KF, Holliday JR, Miake-Lye IM, et al. Synthesizing the strength of the evidence of complementary and integrative health therapies for pain. Pain Med. 2019;20(9):1831-40. doi:10.1093/pm/pnz068; Andrasik F. What does the evidence show? Efficacy of behavioural treatments for recurrent headache in adults. Neurol Sci. 2007;28:70-7. doi:10.1007/s10072-007-0754-8; Wallasch T-M, Kropp P. Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J Headache Pain. 2012;13:521-9. doi:10.1007/s10194-012-0469-y; Gaul C, van Doorn C, Webering N, et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain. 2011;12:475-83. doi:10.1007/s10194-011-0348-y; Wallasch TM, Angeli A, Kropp P. Outcomes of headache-specific cross-sectional multidisciplinary treatment program. Headache. 2012;52(7):1094-105. doi:10.1111/j.1526-4610.2012.02189.x; Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86-92. doi:10.1007/s11916-011-0233-z; Осипова ВВ. Психологические аспекты боли. Неврология, нейропсихиатрия, психосоматика. 2010;2(1):4-8. doi:10.14412/2074-2711-2010-62; Raggi A, Grignani E, Leonardi M, et al. Behavioral Approaches for Primary Headaches: Recent Advances. Headache. 2018;58(6):913-25. doi:10.1111/head.13337; Головачева ВА, Парфенов ВА. Когнитивно-поведенческая терапия в лечении пациентов с мигренью. Неврологический журнал. 2015;3(20):37-43.; Sharpe L, Dudeney J, Williams ACDC, et al. Psychological therapies for the prevention of migraine in adults. Cochrane Database Syst Rev. 2019;7:CD012295. doi:10.1002/14651858.CD012295.pub2; Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81. doi:10.1111/j.1468-1331.2009.02748.x; Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain. 2015;9(4):213-24. doi:10.1177/2049463715578291; Onur OS, Ertem DH, Karsidag C, et al. An open/pilot trial of cognitive behavioral therapy in Turkish patients with refractory chronic migraine. Cogn Neurodyn. 2019 Apr;13(2):183-9. doi:10.1007/s11571-019-09519-y; Otis JD. Managing chronic pain: a cognitive-behavioral therapy: therapist guide. 1 st ed. New York: Oxford University Press; 2007. 114p.; Lee HJ, Lee JH, Cho EY, et al. Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J Headache Pain. 2019;20(1):17. doi:10.1186/s10194-019-0965-4; Anheyer D, Leach MJ, Klose P, et al. Mindfulness-based stress reduction for treating chronic headache: A systematic review and meta-analysis. Cephalalgia. 2019;39(4):544-55. doi:10.1177/0333102418781795; Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2007;128(1-2):111-27. doi:10.1016/j.pain.2006.09.007; Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive eficacy review. Appl Psychophysiol Biofeedback. 2008;33:125-40. doi:10.1007/s10484-008-9060-3; Falsiroli Maistrello L, Geri T, Gianola S, et al. Effectiveness of trigger point manual treatment on the frequency, intensity, and duration of attacks in primary headaches: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2018;9:254. doi:10.3389/fneur.2018.00254; Xu J, Zhang FQ, Pei J, Ji J. Acupuncture for migraine without aura: a systematic review and meta-analysis. J Integr Med. 2018;16(5):312-21. doi:10.1016/j.joim.2018.06.002; Yin Jiang, Peng Bai, Hao Chen, et al. The effect of acupuncture on the quality of life in patients with migraine: a systematic review and meta-analysis. Front Pharmacol. 2018;9:1190. doi:10.3389/fphar.2018.01190; Feng-Jiao Shen, Jia Xu, Yi-Jun Zhan, et al. Acupuncture for migraine: A systematic review and meta-analysis. World J Acupunct Moxibustion. 2019;29(1):7-14. doi:10.1016/j.wjam.2019.03.004; Lemmens J, de Pauw J, van Soom T, et al. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. J Headache Pain. 2019;20(1):16. doi:10.1186/s10194-019-0961-8; Kroll LS, Hammarlund CS, Linde M, et al. The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial. Cephalalgia. 2018;38(12):1805-16. doi:10.1177/0333102417752119; Allen SM, Mookadam F, Cha SS, et al. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018;1(2):211-8. doi:10.3122/jabfm.2018.02.170188; Cuadrado ML, Aledo-Serrano A, Navarro P, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2017;37:864-72. doi:10.1177/0333102416655159; Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebocontrolled study. J Neurol. 2013;260(11):2793-801. doi:10.1007/s00415-013-7072-2; Conforto AB, Amaro E Jr, Goncalves AL, et al. Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. Cephalalgia. 2014;34(6):464-72. doi:10.1177/0333102413515340; Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator. A-randomized-controlled-trial. Neurology. 2013;80:697-704. doi:10.1212/WNL.0b013e3182825055; Chou D, Yugrakh M, Winegarne D, et al. Acute-migraine-therapy-with-external-trigeminal-neurostimulation-ACME-A-randomized-controlled-trial. Cephalalgia. 2019;39(1):3-14. doi:10.1177/0333102418811573; Cadalso RT Jr, Daugherty J, Holmes C, et al. Efficacy of electrical stimulation of the occipital nerve in intractable primary headache disorders: a systematic review with meta-analyses. J Oral Facial Pain Headache. 2018;32(1):40-52. doi:10.11607/ofph.1784; Yang Y, Song M, Fan Y, Ma K. Occipital nerve stimulation for migraine: a systematic review. Pain Pract. 2016;16(4):509-17. doi:10.1111/papr.12303; Schulman EA, Lake AE 3rd , Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778-82. doi:10.1111/j.15264610.2008.01132.x

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1404
https://doi.org/10.14412/2074-2711-2020-4-4-14

View record from BASE

12

Academic Journal

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION ; ОЦЕНКА ФАРМАКОЭКОНОМИЧЕСКОЙ ЦЕЛЕСООБРАЗНОСТИ РАСШИРЕНИЯ ПРАКТИКИ ПРИМЕНЕНИЯ ПРОФИЛАКТИЧЕСКОГО ПОДХОДА К ТЕРАПИИ ГЕМОФИЛИИ А В РОССИЙСКОЙ ФЕДЕРАЦИИ

Συγγραφείς: M. Yu. Frolov, V. A. Rogov, М. Ю. Фролов, В. А. Рогов

Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 10, No 4 (2017); 3-14 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 10, No 4 (2017); 3-14 ; 2070-4933 ; 2070-4909

Θεματικοί όροι: фармакоэкономика, prophylaxis, personalized prophylaxis, cost-effectiveness analysis, pharmacoeconomics, профилактическая терапия, персонифицированная профилактика, анализ «затраты-эффективность»

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/212/207; Клинические рекомендации по диагностике и лечению гемофилии. Под ред. В.Г. Савченко. 2014; 41 с.; Srivastava A. et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19: e1-e47.; Зозуля Н. И., Свирин П. В. Клинические рекомендации по диагностике и лечению гемофилии. Национальное гематологическое общество. 2014.; Руководство по лечению гемофилии. Всемирная Федерация Гемофилии. 2-е изд. Blackwell Publishing Ltd. 2012.; Baolai H., Xiaoyun L., Kuixing L., Adrienne L., Man-Chiu P. Yongqiang Z. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a singlecentre experience from Beijing. Blood Coagulation and Fibrinolysis. 2016; 27 (2): 136-40.; Nilsson IM, Berntop E, Lofqvist T et al. Twenty-five years‘ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992; 232: 25-32.; Aledort, L.M.; Haschmeyer, R.H.; Pettersson, H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J. Intern. Med. 1994; 236: 391-399.; Van den Berg H.M., Fischer K., Mauser-Bunschoten E.P., Beek F.J.A., Roosendaal G., van der Bom J.G., Nieuwenhuis H.K. Long-term outcome in individualized prophylactic treatment of children with severe haemophilia. Br.J Haematol 2001; 112: 561-565.; Funk M. B., Schmidt H., Becker S., Escuriola C., Klarmann D., Klingebiel T., Kreuz W. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia. 2002; 8 (2): 98-103.; Fischer K., Van der Bom J. G., Molho P., Negrier C., MauserBunschoten E. P., Roosendaal G., De Kleijn P., Grobbee D. E., Van Den Berg H. M. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome Haemophilia. 2002; 8 (6): 745-760.; Lundin B., Ljung R., Pettersson H. MRI scores of ankle joints in children with haemophilia – comparison with clinical data. Haemophilia. 2005; 11 (2): 116-122.; Van Dijk K., Fischer K., van der Bom J. G., Grobbee D. E., van den Berg H. M. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed Haemophilia. 2005; 11 (5): 438-443.; Стандарт медицинской помощи больным с наследственным дефицитом фактора VIII, с наследственным дефицитом фактора IX, болезнью Виллебранда от 14 ноября 2007 г. № 705.; Gringeri A., Doralt J., Valentino L A., Crea R. et. al An innovative outcome-based care and procurement model of hemophilia management. Expert Review of Pharmacoeconomics & Outcomes Research. 2016; 16 (3): 337-345.; Manco-Johnson M. J. et al. Randomized, controlled, parallelgroup trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis. 2013; 11 (6): 1119-1127.; Valentino L. A. et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of thrombosis and haemostasis. 2012; 10 (3): 359-367.; Fischer K., de Kleijn P. Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia. 2013; 19 (6): 944-950.; Moroder P., Ernstbrunner L., Zweiger C., Schatz M., Seitlinger G., Skursky R., Long-term results of total knee arthroplasty in aemophilicpatients: an 18-year follow-up. International orthopaedics. 2016; 40 (10): 2115-2120.; Moore M. F., Tobase P., Allen D.D. Meta-analysis: outcomes of total knee arthroplastyin the haemophilia population. Haemophilia. 2016; 22 (4): e275-e285.; Mortazavi S. M. J. Haghpanah, B., Ebrahiminasab, M. M., Baghdadi, T., Toogeh G. Functional outcome of total knee arthroplasty in patientswith haemophilia. Haemophilia. 2016; 22 (6): 919-924.; Rodriguez-Merchan, E.C.Total knee arthroplasty in hemophilic arthropathy. Am. J.Orthop. 2015; 44: 503-507.; Strauss A. C., Rommelspacher Y., Nouri B., Bornemann R., Wimmer M. D., Oldenburg J., Pennekamp P. H., Schmolders J. Longterm outcome of total hip arthroplasty in patients with haemophilia. Haemophilia. 2017; 23 (1): 129-134.; Джалалов С.Ч., Джалалова Д. Х., Хоч Д. С. Интерпретация результатов оценки медицинских технологий. Медицинские технологии. Оценка и выбор. 2014; 4 (18): 19-28.; International Society for Pharmacoeconomics and Outcomes Research URL: http://ispor.org. Дата обращения: 10.09.2017.; https://www.pharmacoeconomics.ru/jour/article/view/212

Διαθεσιμότητα: https://www.pharmacoeconomics.ru/jour/article/view/212
https://doi.org/10.17749/2070-4909.2017.10.4.003-014

View record from BASE

13

Academic Journal